Matching articles for "medroxyprogesterone"
Issue 1748 · February 16, 2026 Free
In Brief: Label Changes for Menopausal Hormone Therapy Products

The FDA has requested the removal of some boxed warnings from the labels of vaginal and systemic menopausal hormone therapy (MHT) products. The warnings were initially added in 2003 based on the results of two…

Med Lett Drugs Ther. 2026 Feb 16; 68(1748):30-1 doi:10.58347/tml.2026.1748d
The FDA has requested the removal of some boxed warnings from the labels of vaginal and systemic menopausal hormone therapy (MHT) products. The warnings were initially added in 2003 based on the results of two placebo-controlled Women's Health Initiative (WHI) trials evaluating the use of systemic hormones for primary prevention of coronary heart disease (CHD) in postmenopausal women 50-79 years old.
Issue 1747 · February 2, 2026 Free
In Brief: New Warning for Injectable Medroxyprogesterone

The FDA now requires that product labels for the long-acting injectable progestin contraceptive medroxyprogesterone acetate (MPA; Depo-Provera CI , and generics; Depo-SubQ Provera 104 ) include a warning about…

Med Lett Drugs Ther. 2026 Feb 2; 68(1747):24 doi:10.58347/tml.2026.1747e
The FDA now requires that product labels for the long-acting injectable progestin contraceptive medroxyprogesterone acetate (MPA; Depo-Provera CI , and generics; Depo-SubQ Provera 104 ) include a warning about the risk of meningioma associated with its use.
Issue 1717 · December 9, 2024 Free
In Brief: Femlyv – An Orally Disintegrating Hormonal Contraceptive

Femlyv (Millicent), an orally disintegrating tablet containing ethinyl estradiol and norethindrone acetate, has been approved by the FDA for prevention of pregnancy in females with a body mass index (BMI)…

Med Lett Drugs Ther. 2024 Dec 9; 66(1717):200 doi:10.58347/tml.2024.1717c
Femlyv (Millicent), an orally disintegrating tablet containing ethinyl estradiol and norethindrone acetate, has been approved by the FDA for prevention of pregnancy in females with a body mass index (BMI) ≤35 kg/m 2 . It is the first hormonal contraceptive to become available in an orally disintegrating tablet formulation. Traditional oral and chewable tablets containing ethinyl estradiol and norethindrone acetate in a wide range of doses, including those found in Femlyv , have been available in the US for years.
Issue 1697 · March 4, 2024
Drugs for Menopausal Symptoms

The primary symptoms of menopause are genitourinary and vasomotor. The genitourinary syndrome of menopause (GSM) includes symptoms such as burning, irritation, dryness, dyspareunia, dysuria, and recurrent…

Med Lett Drugs Ther. 2024 Mar 4; 66(1697):33-8 doi:10.58347/tml.2024.1697a
The primary symptoms of menopause are genitourinary and vasomotor. The genitourinary syndrome of menopause (GSM) includes symptoms such as burning, irritation, dryness, dyspareunia, dysuria, and recurrent urinary tract infection. Vasomotor symptoms (VMS; hot flashes, night sweats) often disrupt sleep.
Issue 1676 · May 15, 2023
Choice of Contraceptives

Intrauterine devices (IUDs) and the etonogestrel implant are the most effective reversible contraceptive methods available. Hormonal oral contraceptives, patches, rings, and injectables are also effective in…

Med Lett Drugs Ther. 2023 May 15; 65(1676):73-80 doi:10.58347/tml.2023.1676a
Intrauterine devices (IUDs) and the etonogestrel implant are the most effective reversible contraceptive methods available. Hormonal oral contraceptives, patches, rings, and injectables are also effective in preventing pregnancy. When used alone, barrier and behavioral methods generally have higher failure rates than other methods (see Table 1). Selection of a contraceptive method is usually based on patient-specific factors and personal preference
Issue 1605 · August 24, 2020
Phexxi - A Nonhormonal Contraceptive Gel

The FDA has approved Phexxi (Evofem), a nonhormonal prescription-only vaginal gel containing lactic acid, citric acid, and potassium bitartrate, for prevention of pregnancy. The gel is intended for on-demand…

Med Lett Drugs Ther. 2020 Aug 24; 62(1605):129-32
The FDA has approved Phexxi (Evofem), a nonhormonal prescription-only vaginal gel containing lactic acid, citric acid, and potassium bitartrate, for prevention of pregnancy. The gel is intended for on-demand contraception; it is not effective when used after intercourse. It was previously approved for use as a vaginal lubricant (Amphora) , but was never marketed.
Issue 1577 · July 29, 2019 Free
Addendum: Estradiol/Progesterone (Bijuva) for Menopausal Vasomotor Symptoms

In our article on Bijuva , the oral fixed-dose combination of estradiol and progesterone (Med Lett Drugs Ther 2019; 61:99) , Table 1 should have included single-ingredient oral formulations of estradiol and…

Med Lett Drugs Ther. 2019 Jul 29; 61(1577):120
In our article on Bijuva , the oral fixed-dose combination of estradiol and progesterone (Med Lett Drugs Ther 2019; 61:99) , Table 1 should have included single-ingredient oral formulations of estradiol and progesterone (see below). They will be added to the table as it appears online, along with medroxyprogesterone ( Provera , and generics), another single-ingredient progestin available for use in women with an intact uterus who take systemic estrogen for menopausal symptoms. Taking generic estradiol and progesterone separately may be less convenient than taking Bijuva , but they cost less and allow for more dosing flexibility.
Issue 1575 · July 1, 2019
Estradiol/Progesterone (Bijuva) for Menopausal Vasomotor Symptoms

The FDA has approved Bijuva (TherapeuticsMD), a fixed-dose combination of estradiol and progesterone, for oral treatment of moderate to severe vasomotor symptoms (hot flashes) due to menopause in women with an…

Med Lett Drugs Ther. 2019 Jul 1; 61(1575):99-101
The FDA has approved Bijuva (TherapeuticsMD), a fixed-dose combination of estradiol and progesterone, for oral treatment of moderate to severe vasomotor symptoms (hot flashes) due to menopause in women with an intact uterus. The manufacturer is marketing Bijuva as "the first and only FDA-approved combination of bio-identical estradiol and bio-identical progesterone in a single daily oral capsule".
Issue 1557 · October 8, 2018
Choice of Contraceptives

Intrauterine devices (IUDs) and the etonogestrel implant are the most effective reversible contraceptive methods available. Hormonal oral contraceptives, patches, rings, and injectables are also highly…

Med Lett Drugs Ther. 2018 Oct 8; 60(1557):161-8
Intrauterine devices (IUDs) and the etonogestrel implant are the most effective reversible contraceptive methods available. Hormonal oral contraceptives, patches, rings, and injectables are also highly effective in preventing pregnancy. When used alone, barrier and fertility-based methods generally have higher failure rates than other methods.
Issue 1507 · November 7, 2016
Drugs for Menopausal Symptoms

The primary symptoms of menopause are genitourinary and vasomotor. A thin, dry vaginal lining and thin urethral mucosa can cause vaginal and vulvar burning and irritation, pain during intercourse, and an…

Med Lett Drugs Ther. 2016 Nov 7; 58(1507):142-5
The primary symptoms of menopause are genitourinary and vasomotor. A thin, dry vaginal lining and thin urethral mucosa can cause vaginal and vulvar burning and irritation, pain during intercourse, and an increased risk of urinary tract infections. Vasomotor symptoms ("hot flashes") cause daytime discomfort and night sweats that may disrupt sleep.
Issue 1441 · April 28, 2014
Conjugated Estrogens/Bazedoxifene (Duavee) for Menopausal Symptoms and Prevention of Osteoporosis

The FDA has approved Duavee (Pfizer), a fixed-dose combination of conjugated estrogens and the new selective estrogen receptor modulator (SERM) bazedoxifene, for treatment of moderate to severe vasomotor…

Med Lett Drugs Ther. 2014 Apr 28; 56(1441):33-4
The FDA has approved Duavee (Pfizer), a fixed-dose combination of conjugated estrogens and the new selective estrogen receptor modulator (SERM) bazedoxifene, for treatment of moderate to severe vasomotor symptoms and for prevention of osteoporosis in postmenopausal women with an intact uterus. Bazedoxifene is an estrogen agonist/antagonist with estrogen-like effects on bone and antiestrogen effects on the uterus. It is the second SERM to be approved for prevention of osteoporosis; raloxifene ( Evista , and generics) has been available as a single agent for this indication since 1997.
Issue 111 · November 1, 2011
Drugs for Postmenopausal Osteoporosis

Osteoporosis is characterized by low bone mass with microarchitectural disruption and skeletal fragility that results in an increased risk of fracture. The diagnosis has traditionally been established by bone…

Treat Guidel Med Lett. 2011 Nov; 9(111):67-74
Osteoporosis is characterized by low bone mass with microarchitectural disruption and skeletal fragility that results in an increased risk of fracture. The diagnosis has traditionally been established by bone densitometry, which is generally reported in terms of standard deviations (SD) from mean values in young adults (T-score). The World Health Organization (WHO) has defined normal bone mineral density (BMD) for women as a value within one SD of the young adult mean. Values 2.5 SD or more below the mean (T score -2.5) are defined as osteoporosis. The WHO has developed a computerized model (FRAX) that predicts the 10-year probability of a hip fracture or any other major osteoporotic fracture based on clinical risk factors and BMD at the femoral neck.
Issue 100 · December 1, 2010
Choice of Contraceptives

The choice of which contraceptive to use may vary from one stage of reproductive life to another. Intrauterine devices (IUDs), progestin implants and sterilization are the most effective contraceptive methods…

Treat Guidel Med Lett. 2010 Dec; 8(100):89-96
The choice of which contraceptive to use may vary from one stage of reproductive life to another. Intrauterine devices (IUDs), progestin implants and sterilization are the most effective contraceptive methods available to women. Hormonal contraceptives, when used correctly, are also highly effective in preventing pregnancy. Barrier and fertility-based methods have the highest rate of failure.
Issue 74 · October 1, 2008
Drugs for Postmenopausal Osteoporosis

Osteoporosis is characterized by low bone mass with microarchitectural disruption and skeletal fragility that results in an increased risk of fracture. The diagnosis has traditionally been established by bone…

Treat Guidel Med Lett. 2008 Oct; 6(74):67-74
Osteoporosis is characterized by low bone mass with microarchitectural disruption and skeletal fragility that results in an increased risk of fracture. The diagnosis has traditionally been established by bone densitometry, which is generally reported in terms of standard deviations (SD) from mean values in young adults (T score). The World Health Organization (WHO) has defined normal bone mineral density (BMD) for women as a value within one SD of the young adult mean. Values 2.5 SD (T score -2.5) or more below the mean are defined as osteoporosis. The WHO has developed a computerized model (FRAX) that predicts the 10-year probability of hip fracture based on clinical risk factors and BMD at the femoral neck.
Issue 1254 · February 12, 2007
Angeliq for Treatment of Menopausal Symptoms

A combination tablet containing estradiol and drospirenone ( Angeliq - Berlex) recently became available for treatment of moderate to severe menopausal symptoms in women with an intact uterus. Since the last…

Med Lett Drugs Ther. 2007 Feb 12; 49(1254):15-6
A combination tablet containing estradiol and drospirenone ( Angeliq - Berlex) recently became available for treatment of moderate to severe menopausal symptoms in women with an intact uterus. Since the last Medical Letter issue reviewing such devices,1 more continuous glucose monitoring (CGM) systems have become available. Five devices available now, and two expected to be marketed soon, are listed in the table on page 14. The FDA has approved continuous glucose devices only for the observation of glucose trends.
Issue 38 · October 1, 2005
Drugs for Prevention and Treatment of Postmenopausal Osteoporosis

Many drugs are now marketed for treatment of postmenopausal osteoporosis, but questions remain about their use.

Treat Guidel Med Lett. 2005 Oct; 3(38):69-74
Many drugs are now marketed for treatment of postmenopausal osteoporosis, but questions remain about their use.
Issue 3 · November 1, 2002
Drugs for Prevention and Treatment of Postmenopausal Osteoporosis

Many drugs are now marketed for treatment of post-menopausal osteoporosis (PD Delmas, Lancet 2002; 359:2018). Prevention of this disorder has been complicated by the news that hormone replacement therapy…

Treat Guidel Med Lett. 2002 Nov; 0(3):13-8
Many drugs are now marketed for treatment of post-menopausal osteoporosis (PD Delmas, Lancet 2002; 359:2018). Prevention of this disorder has been complicated by the news that hormone replacement therapy (HRT), which many women have been taking to prevent osteoporosis, increases the incidence of coronary heart disease and that of breast cancer, stroke and pulmonary embolism as well (Medical Letter 2002; 44:78).
Issue 1141 · October 14, 2002
Generic drugs

When patents expire on brand-name drugs and generic formulations become available, patients and managed care organizations may express a preference for the lower-cost generics. Are they equivalent to the…

Med Lett Drugs Ther. 2002 Oct 14; 44(1141):89-90
When patents expire on brand-name drugs and generic formulations become available, patients and managed care organizations may express a preference for the lower-cost generics. Are they equivalent to the brand-name product?
Issue 1090 · October 16, 2000
Drugs For Prevention and Treament of Postmenopausal Osteoporosis

Many drugs are now marketed for prevention and treatment of postmenopausal osteoporosis. All regimens should include an adequate intake of calcium and vitamin D.

Med Lett Drugs Ther. 2000 Oct 16; 42(1090):97-100
Many drugs are now marketed for prevention and treatment of postmenopausal osteoporosis. All regimens should include an adequate intake of calcium and vitamin D.
Issue 996 · March 14, 1997
Drugs of Choice for Cancer Chemotherapy

The tables that follow list drugs used for treatment of cancer in the USA and Canada and their major adverse effects. The choice of drugs in Table I is based on the opinions of Medical Letter consultants. Some…

Med Lett Drugs Ther. 1997 Mar 14; 39(996):21-8
The tables that follow list drugs used for treatment of cancer in the USA and Canada and their major adverse effects. The choice of drugs in Table I is based on the opinions of Medical Letter consultants. Some drugs are listed for indications for which they have not been approved by the US Food and Drug Administration. For most of the cancers listed, surgery and/or radiation therapy are part of the management of the disease. Anticancer drugs and their adverse effects are listed in Table II.
Issue 941 · February 3, 1995
Choice of Contraceptives

New information about contraceptives continues to become available. The commonly used methods of reversible contraception are listed below.

Med Lett Drugs Ther. 1995 Feb 3; 37(941):9-12
New information about contraceptives continues to become available. The commonly used methods of reversible contraception are listed below.
Issue 885 · December 11, 1992
Choice of Contraceptives

The commonly used methods of reversible contraception are listed in the table below. Additional information is available in RA Hatcher et al, Contraceptive Technology , 1990-1992, 15th ed, New York:Irvington,…

Med Lett Drugs Ther. 1992 Dec 11; 34(885):111-4
The commonly used methods of reversible contraception are listed in the table below. Additional information is available in RA Hatcher et al, Contraceptive Technology , 1990-1992, 15th ed, New York:Irvington, 1990.